[HTML][HTML] The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism
…, LN Varghese, GM Tannahill, EC Hatchell, IJ Majewski… - Immunity, 2013 - cell.com
Mixed lineage kinase domain-like (MLKL) is a component of the "necrosome," the multiprotein
complex that triggers tumor necrosis factor (TNF)-induced cell death by necroptosis. To …
complex that triggers tumor necrosis factor (TNF)-induced cell death by necroptosis. To …
[HTML][HTML] Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression
One of the most common analysis tasks in genomic research is to identify genes that are
differentially expressed (DE) between experimental conditions. Empirical Bayes (EB) statistical …
differentially expressed (DE) between experimental conditions. Empirical Bayes (EB) statistical …
Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
…, T Nguyen, Z Xu, C Flensburg, TE Lew, IJ Majewski… - Cancer discovery, 2019 - AACR
Why CLL recurs in patients who achieve remission with the BCL2 inhibitor venetoclax has
been unknown. We provide the first description of an acquired point mutation in BCL2 arising …
been unknown. We provide the first description of an acquired point mutation in BCL2 arising …
ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity
…, ME Blewitt, A Oshlack, IJ Majewski - Nucleic acids …, 2011 - academic.oup.com
Transcriptional control is dependent on a vast network of epigenetic modifications. One
epigenetic mark of particular interest is tri-methylation of lysine 27 on histone H3 (H3K27me3), …
epigenetic mark of particular interest is tri-methylation of lysine 27 on histone H3 (H3K27me3), …
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
…, D Westerman, EG Si, IJ Majewski… - Blood, The Journal …, 2016 - ashpublications.org
BCL2 blunts activation of the mitochondrial pathway to apoptosis, and high-level expression
is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small…
is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small…
[HTML][HTML] PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer
IJ Majewski, P Nuciforo, L Mittempergher… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose We investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase
(PI3K) catalytic subunit (PIK3CA) correlates with response to neoadjuvant human …
(PI3K) catalytic subunit (PIK3CA) correlates with response to neoadjuvant human …
An α‐E‐catenin (CTNNA1) mutation in hereditary diffuse gastric cancer
IJ Majewski, I Kluijt, A Cats, TS Scerri… - The Journal of …, 2013 - Wiley Online Library
Diffuse gastric cancers typically present as late‐stage tumours and, as a result, the 5 year
survival rate is poor. Some gastric cancers are hereditary and these tend to be of the diffuse …
survival rate is poor. Some gastric cancers are hereditary and these tend to be of the diffuse …
Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive …
…, S Fleming, FC Brown, S Loo, IJ Majewski… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in
acute myeloid leukemia (AML), with promising response rates in combination with …
acute myeloid leukemia (AML), with promising response rates in combination with …
[HTML][HTML] Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
…, P Blombery, G Lessene, IJ Majewski… - Nature …, 2019 - nature.com
Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery
promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with …
promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with …
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
…, S Banquet, IJ Majewski… - Blood, The Journal …, 2021 - ashpublications.org
Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative
treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-…
treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-…